The Migraine Drugs Market Demand is witnessing a remarkable surge, fueled primarily by growing awareness among patients and healthcare providers. This dynamic market is expected to grow from $5.47 billion in 2024 to an estimated $8.12 billion by 2035, reflecting a compound annual growth rate (CAGR) of 3.65%. The rising prevalence of migraines globally, coupled with improved access to...

The Migraine Drugs Market is experiencing robust growth as the acute treatment segment evolves beyond traditional triptans and nonsteroidal anti-inflammatory drugs to embrace novel, rapidly acting mechanisms that address the limitations of existing options. Many migraine patients experience inadequate response, recurrence, or contraindications to triptans, while others develop...